Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00270829 · ClinicalTrials.gov registry record · Phase 4
Renal Effects of Intrarenal Nesiritide
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT00270829 is a Phase 4 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 2 participants.
The verdict
NCT00270829, a Phase 4 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The impact of nesiritide in CHF is unclear, but it is possible that systemic vasodilation leads to adverse consequences even if the direct renal effects are positive. Therefore, this study will look at the effects of direct intrarenal administration of nesiritide on GFR and RPF.
Interventions
- DRUG nesiritide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00270829
The ClinicalTrials.gov registry entry for NCT00270829 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nesiritide is the first listed.
NCT00270829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00270829 about?
NCT00270829 is a clinical study titled "Renal Effects of Intrarenal Nesiritide". The impact of nesiritide in CHF is unclear, but it is possible that systemic vasodilation leads to adverse consequences even if the direct renal effects are positive. Therefore, this study will look at the effects of direct intrarenal administration of nesiritide on GFR and RPF.
What is the current status of trial NCT00270829?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2005-12. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00270829?
The interventions under investigation include: nesiritide (DRUG).
Who is sponsoring clinical trial NCT00270829?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.